Marine n-3 fatty acids, atrial fibrillation and QT-interval in haemodialysis patients

Ellen Kirkegaard, My Svensson, Charlotte Strandhave, Erik Berg Schmidt, Kaj Anker Jørgensen, Jeppe Hagstrup Christensen

    Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

    Abstract

    Patients treated with haemodialysis are at high risk of sudden cardiac death (SCD) often caused by arrhythmias. Atrial fibrillation (AF) is frequent among haemodialysis patients and is associated with increased mortality. Prolonged QTc is a risk marker of ventricular arrhythmia and is thereby associated with SCD. Studies have suggested that n-3 PUFA may have an antiarrhythmic effect, but the exact mechanism is not clear. The aim of this study was to examine whether AF was associated with n-3 PUFA in plasma phospholipids and whether supplementation with n-3 PUFA would shorten the QTc interval in haemodialysis patients compared to placebo. In a double-blinded randomised, placebo-controlled intervention trial 206 haemodialysis patients with CVD were treated with 1·7 g n-3 PUFA or placebo (olive oil) daily for 3 months. Blood samples and electrocardiogram evaluations were carried out at baseline and after 3 months. The QT interval, PQ interval and heart rate were measured in all patients with sinus rhythm (SR). At baseline 13 % of patients had AF. The content of the n-3 PUFA, DHA, was significantly lower (P 
    OriginalsprogEngelsk
    TidsskriftBritish Journal of Nutrition
    Vol/bind107
    Nummer6
    Sider (fra-til)903-9
    Antal sider7
    ISSN0007-1145
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Marine n-3 fatty acids, atrial fibrillation and QT-interval in haemodialysis patients'. Sammen danner de et unikt fingeraftryk.

    Citationsformater